DNMT3A and cyclic hematopoiesis: A recent analysis of the results of the FIRE-3 trial for metastatic colorectal cancer was able to focus primarily on CH and outcomes in metastatic cancer, finding that 36% of the patients in the trial had CH and that CH was associated with improved survival outcomes—driven specifically by mutations in DNMT3A.